Categories: Health

Statins for primary prevention of cardiovascular disease in people with HIV

Compilation
GeSIDA, AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology (Seimts), published a position paper on the use Statins in primary prevention of cardiovascular diseases in people with HIVThe main recommendation based on the Reprive clinical trial is: Consider prescribing statins to people with HIV over 40 years of age with low or moderate cardiovascular risk..

The Reprive study demonstrates a reduction in cardiovascular events in primary prevention with this type of lipid-lowering drug in people who do not have high cardiovascular risk.

The Reprive study is the first large-scale clinical trial to evaluate the prevention of cardiovascular disease in people with HIV, demonstrating that use of statins for primary prevention significantly reduces cardiovascular events

even in individuals without high risk.

Hesida’s paper highlights the importance of early offer of statin treatment to people with HIV over 40 years of age after assessing their cardiovascular risk using scores such as Ascvd or Regicor. If the risk of Ascvd below 5% in 10 yearswill be considered individualized A moderate activity statin. In case the risk of Ascvd is between 5 and 10% at 10 years old, and Moderately active statin. If the risk of Ascvd more than 10%A statins and a goal of lowering LDL cholesterol will be set. according to clinical guidelines aimed at the general population. Pitavastatin (4 mg) is the recommended moderate-potency statin, followed by alternatives such as atorvastatin (20 mg) or rosuvastatin (10 mg).

Hesida emphasizes that, in general, “the expected benefits of primary prevention of cardiovascular disease with statins outweigh the risks of side effects.”

Engaging primary health care and facilitating access

In addition, Hesida emphasizes the need to involve doctors in primary care and other experts in the prevention of cardiovascular disease in people with HIV. In addition, it emphasizes the importance of taking global approach This includes lifestyle changes and quitting smoking. One of the problems identified is cost of treatmentwhich can impact patient adherence to treatment. Hesida calls on regional health systems and the national system facilitate access to these treatmentsensuring that they do not represent an additional financial burden for patients.

The document also discusses possible interactions

statins with antiretroviral treatment, recommending pitavastatin and rosuvastatin as the options with the lowest risk of interactions. Although statin treatment generally has a low risk of side effects, studies such as Reprive have seen an increase in diabetes and myopathy. However, Ghesida concludes that in general «expected benefits from Primary cardiovascular prevention with statins outweighs risks of side effects“.

Source link

Admin

Share
Published by
Admin

Recent Posts

Find out about the changes coming to your iPhone

The second beta version of iOS 18.2 is now available and includes changes to the…

3 mins ago

What time is Real Madrid – Milan? TV, schedule, where and how to watch the Champions League online today

Football returns to the Bernabeu. The Madrid temple opens its doors after his team lost…

4 mins ago

What can you choose? All new products at the moment

Winter is coming and it's time for frost and humidity. This is where the good…

49 mins ago

Kamala Harris ends her campaign in Philadelphia with an optimistic message: “Yes, she can”

In front of the ladder symbol of resistance, Kamala Harris ended her campaign this Monday…

52 mins ago

Oncologists demand gender differentiation in lung cancer clinical trials

Head of the Department of Oncology at the University Hospital of La Paz and vice-president…

54 mins ago

Ibex 35 waits in “no man’s land” for the outcome of the duel between Kamala Harris and Donald Trump

The futures market is looking for a higher opening on European stock markets as well…

1 hour ago